Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms

Merck's KEYTRUDA combined with Gilead's Trodelvy demonstrated a 35% reduction in the risk of disease progression or death compared to KEYTRUDA plus chemotherapy as a first-line treatment for PD-L1+ inoperable locally advanced or metastatic triple-negative breast cancer. The Phase 3 ASCENT-04/KEYNOTE-D19 study showed a median progression-free survival of 11.2 months for the KEYTRUDA/Trodelvy combination versus 7.8 months for KEYTRUDA/chemotherapy, with a consistent safety profile.

Analysis

Merck & Co. (MRK) has announced significant positive outcomes from its pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study, where its leading immunotherapy, KEYTRUDA (pembrolizumab), in combination with Gilead Sciences' (GILD) TROP2 antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy), reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus chemotherapy. This result pertains to the first-line treatment of patients with PD-L1 positive (Combined Positive Score [CPS] ≥10) inoperable locally advanced or metastatic triple-negative breast cancer (TNBC). The combination therapy demonstrated a median progression-free survival (PFS) of 11.2 months, a substantial improvement over the 7.8 months recorded for the KEYTRUDA plus chemotherapy arm. Crucially, the safety profile of the KEYTRUDA plus Trodelvy regimen was consistent with the known safety profiles of each individual drug, and no new safety signals were identified. These findings, which are slated for a late-breaking oral presentation, highlight the potential for this combination to establish a new, more effective standard of care in a difficult-to-treat cancer population, thereby potentially expanding the market for both KEYTRUDA and Trodelvy. The strongly positive sentiment indicated for both Merck (0.85) and Gilead (0.7) underscores the clinical and market significance of these trial results.

Key Decisions for Investors

• Investors should consider these positive Phase 3 results as supportive for Merck's (MRK) KEYTRUDA franchise, potentially expanding its market dominance, and for Gilead's (GILD) Trodelvy, significantly enhancing its commercial prospects in the challenging TNBC indication.
• Monitoring the upcoming full data presentation from the ASCENT-04/KEYNOTE-D19 study and subsequent regulatory interactions will be crucial, as these events represent key near-term catalysts for both MRK and GILD.
• The demonstrated 35% risk reduction in disease progression or death and improved median PFS, coupled with a consistent safety profile, suggests potential for rapid clinical adoption post-approval, warranting attention from investors seeking growth opportunities in the oncology sector.